CARLSBAD, California, April 02, 2025 (GLOBE NEWSWIRE) -- Aurora Spine Corporation ('Aurora Spine' or the 'Company') (TSXV: ASG) (OTCQB: ASAPF), a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, today announced the publication of a new clinical study titled 'Fixation of the Sacroiliac Joint: A Cadaver-Based Concurrent-Controlled Biomechanical Comparison of Posterior Interposition and Posterolateral Transosseous Techniques' in the journal .

卡尔斯巴德，加利福尼亚，2025年4月2日（环球新闻社）-- Aurora Spine公司（“Aurora Spine”或“公司”）（TSXV：ASG）（OTCQB：ASAPF），一家设计和制造创新医疗设备以改善脊柱手术效果的公司，今天宣布发表了一项新的临床研究，题为《骶髂关节固定：基于尸体的后路嵌入与后外侧经骨技术的同期对照生物力学比较》，该研究发表在期刊上。

Neurospine

神经脊柱

. The study evaluates the biomechanical performance of Aurora Spine's SiLO TFX™ MIS Sacroiliac Joint Fixation System compared to traditional posterolateral transosseous techniques.​

该研究评估了极光脊柱公司的SiLO TFX™微创骶髂关节固定系统与传统的后外侧经骨技术相比的生物力学性能。​

The SiLO TFX™ system is a minimally invasive solution designed for sacroiliac joint fusion, addressing conditions such as sacroiliac joint disruptions and degenerative sacroiliitis. The system includes a Transfixing-Cone, an ilium screw, a sacrum screw, and associated instrumentation, engineered to transfix the sacrum and ilium, thereby providing stability conducive to bony fusion.

SiLO TFX™ 系统是一种微创解决方案，专为骶髂关节融合设计，用于治疗骶髂关节紊乱和退行性骶髂关节炎等病症。该系统包括一个横贯锥、髂骨螺钉、骶骨螺钉及相关器械，旨在贯穿固定骶骨和髂骨，从而提供有助于骨融合的稳定性。

The SiLO TFX™ system is designed in accordance with the AO Principles of Fusion—providing mechanical stability, preserving vascular supply, minimizing soft tissue disruption, and promoting an optimal environment for bone healing by proper decortication and the use of bone graft..

SiLO TFX™ 系统根据 AO 融合原则设计——提供机械稳定性，保护血管供应，尽量减少软组织损伤，并通过适当的去皮质和使用骨移植来为骨骼愈合创造最佳环境。

The study's findings indicate that the posterior interposition technique, as employed by the SiLO TFX system, removes less bone volume and offers a larger surface area for bony fusion compared to the posterolateral transosseous technique. Specifically, the posterior interposition technique resulted in a 42% ± 8% reduction in nutation/counternutation motion of the sacroiliac joint, outperforming the 14% ± 4% reduction observed with the posterolateral transosseous technique.

研究结果表明，与后外侧经骨技术相比，SiLO TFX系统采用的后路嵌入技术去除的骨量更少，并为骨融合提供了更大的表面积。具体而言，后路嵌入技术使骶髂关节的点头/反点头运动减少了42% ± 8%，优于后外侧经骨技术所观察到的14% ± 4%的减少。

Furthermore, upon fatigue loading, the posterior interposition implant maintained the bone-implant interface across all specimens, whereas the posterolateral transosseous implant exhibited migration or subsidence in 20%–50% of specimens. .

此外，在疲劳加载时，后部嵌入植入物在所有样本中都保持了骨-植入物界面的稳定性，而后外侧经骨植入物则在20%-50%的样本中表现出移位或下沉。

Trent Northcutt, President and CEO of Aurora Spine, expressed satisfaction with the outcomes of the biomechanical study conducted. 'The study demonstrated the superior performance of the SiLO TFX system in sacroiliac joint fusion. These findings align with Aurora Spine’s commitment to developing innovative, minimally invasive solutions that optimize patient outcomes and establish new standards in sacroiliac joint care.​'​ .

Aurora Spine的总裁兼首席执行官特伦特·诺斯科特对这项生物力学研究的结果表示满意。“研究表明，SiLO TFX系统在骶髂关节融合中的表现非常出色。这些发现与Aurora Spine致力于开发创新、微创的解决方案以优化患者疗效，并在骶髂关节护理中树立新标准的承诺高度一致。”

Dr. Michael Stoffman, University at Buffalo Neurosurgery, Buffalo, NY, one of the study's authors, stated: '​The posterior interposition technique demonstrated significant advantages in reducing joint motion and preserving bone integrity. This approach offers a promising alternative to traditional methods, potentially leading to improved patient recovery and long-term success.' .

布法罗大学神经外科（纽约州布法罗）的迈克尔·斯托夫曼博士，该研究的作者之一，表示：“后路嵌入技术在减少关节活动和保持骨骼完整性方面展现了显著优势。这种方法为传统方法提供了一个有前景的替代方案，可能有助于改善患者的恢复效果和长期成功率。”

Dr. Steven M. Falowski from Neurosurgical Associates of Lancaster, Lancaster, PA added: '​Our research indicates that the SiLO TFX system provides enhanced stability and durability in sacroiliac joint fixation. The reduced bone removal and increased fusion surface area are critical factors in achieving successful surgical outcomes.'​ .

兰卡斯特神经外科协会（宾夕法尼亚州兰卡斯特）的史蒂文·M·法洛夫斯基博士补充说：‘我们的研究表明，SiLO TFX系统在骶髂关节固定中提供了更高的稳定性和耐久性。减少骨头去除和增加融合表面积是实现手术成功结果的关键因素。’

Dr. Jason E. Pope, Evolve Restorative Center, Santa Rosa, CA, remarked: '​The study's outcomes highlight the biomechanics of the posterior interposition technique in sacroiliac joint fusion. The data suggests it is a viable treatment option for those suffering from sacroiliac joint disease and future clinical data on safety and efficacy is ongoing.'​ .

杰森·E·波普博士（Dr. Jason E. Pope），来自加利福尼亚州圣罗莎的Evolve Restorative Center，评论道：“该研究的结果突显了骶髂关节融合术中后路嵌入技术的生物力学特性。数据表明，对于患有骶髂关节疾病的患者来说，这是一种可行的治疗选择，关于安全性和有效性的未来临床数据仍在收集中。”

Aurora Spine remains dedicated to advancing spinal health through continuous innovation and collaboration with leading medical professionals. The publication of this study reinforces the company's position at the forefront of spinal implant technology.​

极光脊柱公司仍致力于通过持续创新和与领先的医疗专业人员合作来推动脊柱健康的发展。这项研究的发表进一步巩固了该公司在脊柱植入技术前沿的地位。​

About Aurora Spine

关于极光脊柱

Aurora Spine is focused on bringing new solutions to the spinal implant market through a series of innovative, minimally invasive, regenerative spinal implant technologies.

Aurora Spine 专注于通过一系列创新的、微创的、再生的脊柱植入技术，为脊柱植入市场带来新的解决方案。

For more information about Aurora Spine and the SiLO TFX MIS Sacroiliac Joint Fixation System, please visit

有关Aurora Spine和SiLO TFX MIS骶髂关节固定系统的更多信息，请访问

www.aurora-spine.com

www.aurora-spine.com

.

。

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

多伦多证券交易所创业板及其监管服务提供商（该术语在TSX创业交易所政策中定义）均不对本发布的充分性或准确性承担责任。

Forward-Looking Statements

前瞻性声明

This news release contains forward-looking information that involves substantial known and unknown risks and uncertainties, most of which are beyond the control of Aurora Spine, including, without limitation, those listed under 'Risk Factors' and 'Cautionary Statement Regarding Forward-Looking Information' in Aurora Spine's final prospectus (collectively, 'forward-looking information').

本新闻稿包含前瞻性信息，其中涉及大量已知和未知的风险和不确定性，其中大多数是Aurora Spine无法控制的，包括但不限于在Aurora Spine最终招股说明书中列出的“风险因素”和“关于前瞻性信息的警示声明”中提到的内容（统称为“前瞻性信息”）。

Forward-looking information in this news release includes information concerning the proposed use and success of the Company's products in surgical procedures. Aurora Spine cautions investors of Aurora Spine's securities about important factors that could cause Aurora Spine's actual results to differ materially from those projected in any forward-looking statements included in this news release.

本新闻稿中的前瞻性信息包括有关公司产品在手术中拟议使用和成功的相关信息。Aurora Spine提醒Aurora Spine证券的投资者注意可能导致Aurora Spine的实际结果与本新闻稿中包含的任何前瞻性声明中预测的结果有重大差异的重要因素。

Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ unilaterally from those expressed in such forward-looking statements.

任何表达或涉及对预期、信念、计划、目标、假设或未来事件或表现的讨论的声明都不是历史事实，可能是前瞻性的，可能包含估计、假设和不确定性，这些可能导致实际结果或结果与这些前瞻性声明中单方面表达的内容有所不同。

No assurance can be given that the expectations set out herein will prove to be correct and, accordingly, prospective investors should not place undue reliance on these forward-looking statements. These statements speak only as of the date of this press release, and Aurora Spine does not assume any obligation to update or revise them to reflect new events or circumstances.

无法保证本文所述的预期将被证明是正确的，因此，潜在投资者不应过分依赖这些前瞻性陈述。这些陈述仅截至本新闻稿发布之日，Aurora Spine 不承担任何更新或修改这些陈述以反映新事件或情况的义务。

.

。

Contact:

联系：

‎Aurora Spine Corporation

极光脊柱公司

Trent Northcutt

特伦特·诺斯卡特

‎President and Chief Executive Officer

总裁兼首席执行官

‎(760) 424-2004

（760）424-2004

Chad Clouse

查德·克劳斯

‎Chief Financial Officer

首席财务官

‎(760) 424-2004

（760）424-2004

‎

www.aurora-spine.com

www.aurora-spine.com